Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report

A. U. Buzdar; G. R. Blumenschein; J. U. Gutterman; C. K. Tashima; G. N. Hortobagyi; T. L. Smith; L. T. Campos; W. L. Wheeler; Evan M Hersh; E. J. Freireich; E. A. Gehan

doi:10.1001/jama.242.14.1509

Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report

A. U. Buzdar, G. R. Blumenschein, J. U. Gutterman, C. K. Tashima, G. N. Hortobagyi, T. L. Smith, L. T. Campos, W. L. Wheeler, Evan M Hersh, E. J. Freireich, E. A. Gehan

Research output: Contribution to journal › Article

Abstract

222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.

Original language	English (US)
Pages (from-to)	1509-1513
Number of pages	5
Journal	Journal of the American Medical Association
Volume	242
Issue number	14
DOIs	https://doi.org/10.1001/jama.242.14.1509
State	Published - 1979
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.242.14.1509

Fingerprint Dive into the research topics of 'Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report'. Together they form a unique fingerprint.

Cite this

Buzdar, A. U., Blumenschein, G. R., Gutterman, J. U., Tashima, C. K., Hortobagyi, G. N., Smith, T. L., Campos, L. T., Wheeler, W. L., Hersh, E. M., Freireich, E. J., & Gehan, E. A. (1979). Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. Journal of the American Medical Association, 242(14), 1509-1513. https://doi.org/10.1001/jama.242.14.1509

Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. / Buzdar, A. U.; Blumenschein, G. R.; Gutterman, J. U.; Tashima, C. K.; Hortobagyi, G. N.; Smith, T. L.; Campos, L. T.; Wheeler, W. L.; Hersh, Evan M; Freireich, E. J.; Gehan, E. A.

In: Journal of the American Medical Association, Vol. 242, No. 14, 1979, p. 1509-1513.

Research output: Contribution to journal › Article

Buzdar, AU, Blumenschein, GR, Gutterman, JU, Tashima, CK, Hortobagyi, GN, Smith, TL, Campos, LT, Wheeler, WL, Hersh, EM, Freireich, EJ & Gehan, EA 1979, 'Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report', Journal of the American Medical Association, vol. 242, no. 14, pp. 1509-1513. https://doi.org/10.1001/jama.242.14.1509

Buzdar, A. U. ; Blumenschein, G. R. ; Gutterman, J. U. ; Tashima, C. K. ; Hortobagyi, G. N. ; Smith, T. L. ; Campos, L. T. ; Wheeler, W. L. ; Hersh, Evan M ; Freireich, E. J. ; Gehan, E. A. / Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. In: Journal of the American Medical Association. 1979 ; Vol. 242, No. 14. pp. 1509-1513.

@article{9d690afd7c294a2ba6dc6e61424488e2,

title = "Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report",

abstract = "222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.",

author = "Buzdar, {A. U.} and Blumenschein, {G. R.} and Gutterman, {J. U.} and Tashima, {C. K.} and Hortobagyi, {G. N.} and Smith, {T. L.} and Campos, {L. T.} and Wheeler, {W. L.} and Hersh, {Evan M} and Freireich, {E. J.} and Gehan, {E. A.}",

year = "1979",

doi = "10.1001/jama.242.14.1509",

language = "English (US)",

volume = "242",

pages = "1509--1513",

journal = "JAMA - Journal of the American Medical Association",

issn = "0002-9955",

publisher = "American Medical Association",

number = "14",

}

TY - JOUR

T1 - Postoperative adjuvant Chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report

AU - Buzdar, A. U.

AU - Blumenschein, G. R.

AU - Gutterman, J. U.

AU - Tashima, C. K.

AU - Hortobagyi, G. N.

AU - Smith, T. L.

AU - Campos, L. T.

AU - Wheeler, W. L.

AU - Hersh, Evan M

AU - Freireich, E. J.

AU - Gehan, E. A.

PY - 1979

Y1 - 1979

N2 - 222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.

AB - 222 patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and BCG vaccine. At 54 months of study (median follow-up, 30 months), the estimated proportions remaining disease-free two and three years after surgery were 83% and 78%, respectively, in the chemotherapy group and 64% and 55%, respectively, in 151 historical control patients. Estimated two- and three-year survival rates were 93% and 89%, respectively, in the chemotherapy group and 84% and 58%, respectively, in the control patients. Congestive heart failure has developed in three patients, possibly related to the use of doxorubicin. Adjuvant chemotherapy with these drugs was effective in prolonging the disease-free interval and survival of patients irrespective of menopausal status, degree of nodal involvement, or stage of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0018675124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018675124&partnerID=8YFLogxK

U2 - 10.1001/jama.242.14.1509

DO - 10.1001/jama.242.14.1509

M3 - Article

C2 - 470088

VL - 242

SP - 1509

EP - 1513

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 14

ER -